The stock of Maravai LifeSciences Holdings Inc (MRVI) has seen a -4.52% decrease in the past week, with a -28.77% drop in the past month, and a -13.39% decrease in the past quarter. The volatility ratio for the week is 7.63%, and the volatility levels for the past 30 days are at 7.48% for MRVI. The simple moving average for the last 20 days is -12.51% for MRVI stock, with a simple moving average of -45.35% for the last 200 days.
Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?
The 36-month beta value for MRVI is also noteworthy at -0.06. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRVI is 117.88M, and at present, short sellers hold a 7.24% of that float. The average trading volume of MRVI on February 25, 2025 was 1.97M shares.
MRVI) stock’s latest price update
The stock price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has plunged by -2.43 when compared to previous closing price of 4.11, but the company has seen a -4.52% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-02-24 that SAN DIEGO–(BUSINESS WIRE)–Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio’s AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies’ leading drug substance manufacturing capabilities, providing customers comprehensive expertise and n.
Analysts’ Opinion of MRVI
Goldman, on the other hand, stated in their research note that they expect to see MRVI reach a price target of $4.25. The rating they have provided for MRVI stocks is “Sell” according to the report published on December 05th, 2024.
MRVI Trading at -21.16% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.30% of loss for the given period.
Volatility was left at 7.48%, however, over the last 30 days, the volatility rate increased by 7.63%, as shares sank -28.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.15% lower at present.
During the last 5 trading sessions, MRVI fell by -4.52%, which changed the moving average for the period of 200-days by -55.49% in comparison to the 20-day moving average, which settled at $4.58. In addition, Maravai LifeSciences Holdings Inc saw -26.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from ORESHACK KURT, who sale 25,000 shares at the price of $5.03 back on Jan 31 ’25. After this action, ORESHACK KURT now owns 167,618 shares of Maravai LifeSciences Holdings Inc, valued at $125,750 using the latest closing price.
ORESHACK KURT, the Officer of Maravai LifeSciences Holdings Inc, proposed sale 25,000 shares at $5.03 during a trade that took place back on Jan 31 ’25, which means that ORESHACK KURT is holding shares at $125,750 based on the most recent closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.44 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.81. The total capital return value is set at -0.16. Equity return is now at value -51.98, with -12.67 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at 1.63. The interest coverage ratio of the stock is -3.77.
Currently, EBITDA for the company is 712.41 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1.99. The receivables turnover for the company is 9.59for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.74.
Conclusion
In summary, Maravai LifeSciences Holdings Inc (MRVI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
